What happens when an approved drug doesn’t work?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more.

The need-to-know this morning

• Bristol Myers Squibb won FDA approval to expand the use of its Breyanzi CAR-T treatment to include patients with chronic lymphocytic leukemia. Breyanzi, already approved for lymphoma, is the first personalized cell therapy to receive an additional regulatory clearance to treat this type of blood cancer.

Madrigal wins first approval for MASH drug

The FDA yesterday granted an accelerated approval for the first medicine to treat MASH. The pill, made by Madrigal Pharmaceuticals, is called Rezdiffra. MASH is a serious liver disease that is linked to obesity and causes inflammation and scarring. It can ultimately lead to cirrhosis and cancer, and many patients ultimately need liver transplants.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In